PHLAX: PGIM Jennison Health Sciences Fund - MutualFunds.com

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Fixed income news, reports, video and more.

Municipal bonds news, reports, video and more.

Practice management news, reports, video and more.

Portfolio management news, reports, video and more.

Retirement news, reports, video and more.

Learn from industry thought leaders and expert market participants.

Deepen your understanding of Responsible Investing.

Enhance retirement outcomes with helpful tactics.

PGIM Jennison Health Sciences A

PHLAX - Snapshot

Vitals

  • YTD Return 28.3%
  • 3 Yr Annualized Return 12.8%
  • 5 Yr Annualized Return 9.0%
  • Net Assets $1.98 B
  • Holdings in Top 10 30.2%

52 WEEK LOW AND HIGH

$55.89
$32.11
$56.99

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.15%

SALES FEES

  • Front Load 5.50%
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 30.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

Closed to new investors as of Jun 29, 2012
  • Standard (Taxable) $2,500
  • IRA $1,000

Fund Classification


Compare PHLAX to Popular Health Care Sector Equity Funds and ETFs

Overview

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

$220.28

-0.36%

$46.04 B

1.10%

$2.43

5.80%

-

$108.52

-0.26%

$22.44 B

1.51%

$1.65

6.85%

-

$98.93

-0.05%

$15.09 B

0.05%

$0.05

21.49%

-

$106.28

-0.13%

$12.74 B

1.20%

$1.27

10.77%

-

$212.35

-0.23%

$12.74 B

1.20%

$2.55

10.86%

-

PHLAX - Profile

Distributions

  • YTD Total Return 28.3%
  • 3 Yr Annualized Total Return 10.7%
  • 5 Yr Annualized Total Return 7.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.57%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    PGIM Jennison Health Sciences Fund
  • Fund Family Name
    PGIM Funds (Prudential)
  • Inception Date
    Jun 30, 1999
  • Shares Outstanding
    N/A
  • Share Class
    A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    David Chan

Fund Description

The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.


PHLAX - Performance

Return Ranking - Trailing

Period PHLAX Return Category Return Low Category Return High Rank in Category (%)
YTD 28.3% -6.0% 122.9% 10.56%
1 Yr 31.3% -1.4% 132.6% 18.13%
3 Yr 12.8%* 0.8% 40.7% 32.17%
5 Yr 9.0%* -0.7% 29.6% 48.57%
10 Yr 17.4%* 8.1% 19.7% 17.89%

* Annualized

Return Ranking - Calendar

Period PHLAX Return Category Return Low Category Return High Rank in Category (%)
2019 14.5% 3.8% 63.8% 84.14%
2018 -14.8% -49.7% 21.5% 83.94%
2017 24.9% -59.8% 54.4% 22.22%
2016 -17.7% -36.6% 11.6% 64.34%
2015 -8.5% -62.4% 27.9% 84.43%

Total Return Ranking - Trailing

Period PHLAX Return Category Return Low Category Return High Rank in Category (%)
YTD 28.3% -6.0% 129.9% 10.56%
1 Yr 24.1% -6.5% 132.6% 32.50%
3 Yr 10.7%* -0.3% 40.7% 51.75%
5 Yr 7.8%* -0.7% 29.6% 55.00%
10 Yr 16.8%* 8.1% 19.7% 25.20%

* Annualized

Total Return Ranking - Calendar

Period PHLAX Return Category Return Low Category Return High Rank in Category (%)
2019 14.5% 3.8% 63.8% 84.14%
2018 -14.8% -25.3% 22.2% 85.40%
2017 24.9% -10.8% 54.4% 23.70%
2016 -17.7% -36.6% 11.6% 74.42%
2015 -8.5% -16.6% 27.9% 88.52%

NAV & Total Return History


PHLAX - Holdings

Concentration Analysis

PHLAX Category Low Category High PHLAX % Rank
Net Assets 1.98 B 3.74 M 46 B 24.42%
Number of Holdings 87 24 426 62.21%
Net Assets in Top 10 601 M 952 K 19.6 B 37.21%
Weighting of Top 10 30.20% 14.0% 75.7% 83.14%

Top 10 Holdings

  1. UnitedHealth Group Inc 5.49%
  2. Immunomedics Inc 4.95%
  3. Natera Inc 3.08%
  4. AstraZeneca PLC ADR 3.06%
  5. Abbott Laboratories 3.03%
  6. Humana Inc 3.02%
  7. Sarepta Therapeutics Inc 2.85%
  8. Eli Lilly and Co 2.44%
  9. DexCom Inc 2.44%
  10. Boston Scientific Corp 2.43%

Asset Allocation

Weighting Return Low Return High PHLAX % Rank
Stocks
99.27% 61.47% 102.50% 34.30%
Cash
0.70% -0.01% 32.46% 57.56%
Preferred Stocks
0.03% 0.00% 6.63% 13.95%
Other
0.00% -2.50% 6.07% 37.79%
Convertible Bonds
0.00% 0.00% 0.06% 12.79%
Bonds
0.00% 0.00% 16.11% 15.12%

Stock Sector Breakdown

Weighting Return Low Return High PHLAX % Rank
Healthcare
97.91% 61.81% 100.00% 81.98%
Financial Services
1.23% 0.00% 3.31% 2.91%
Basic Materials
0.86% 0.00% 2.60% 6.98%
Utilities
0.00% 0.00% 0.00% 11.63%
Technology
0.00% 0.00% 15.86% 24.42%
Real Estate
0.00% 0.00% 6.03% 17.44%
Industrials
0.00% 0.00% 5.94% 20.93%
Energy
0.00% 0.00% 0.00% 11.63%
Communication Services
0.00% 0.00% 4.69% 15.12%
Consumer Defense
0.00% 0.00% 34.31% 17.44%
Consumer Cyclical
0.00% 0.00% 1.09% 18.60%

Stock Geographic Breakdown

Weighting Return Low Return High PHLAX % Rank
US
83.51% 47.91% 99.98% 41.28%
Non US
15.76% 0.00% 43.79% 53.49%

PHLAX - Expenses

Operational Fees

PHLAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.15% 0.08% 25.14% 43.37%
Management Fee 0.72% 0.00% 1.25% 60.47%
12b-1 Fee 0.30% 0.00% 1.00% 56.00%
Administrative Fee N/A 0.03% 0.40% N/A

Sales Fees

PHLAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load 5.50% 3.50% 5.75% 60.87%
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

PHLAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PHLAX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 30.00% 0.70% 252.00% 31.29%

PHLAX - Distributions

Dividend Yield Analysis

PHLAX Category Low Category High PHLAX % Rank
Dividend Yield 0.00% 0.00% 3.15% 26.74%

Dividend Distribution Analysis

PHLAX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Semi-Annually Annually

Net Income Ratio Analysis

PHLAX Category Low Category High PHLAX % Rank
Net Income Ratio -0.57% -2.53% 2.53% 83.23%

Capital Gain Distribution Analysis

PHLAX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Semi-Annually

Dividend Payout History

View More +

PHLAX - Fund Manager Analysis

Managers

David Chan


Start Date

Tenure

Tenure Rank

Jun 30, 1999

21.35

21.4%

David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.

Debra Netschert


Start Date

Tenure

Tenure Rank

Jan 28, 2015

5.76

5.8%

Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.09 23.14 7.28 20.52